- Home
- AURA
as 11-03-2025 4:00pm EST
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 396.8M | IPO Year: | 2021 |
| Target Price: | $21.80 | AVG Volume (30 days): | 302.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.34 - $11.29 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Aura Biosciences Inc. (AURA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| de los Pinos Elisabet | AURA | See Remarks | Oct 29 '25 | Sell | $6.35 | 9,049 | $57,461.15 | 474,391 | |
| Elazzouzi Amy | AURA | Senior Vice President, Finance | Oct 29 '25 | Sell | $6.35 | 896 | $5,689.60 | 85,662 | |
| Plavsic Mark | AURA | Chief Technology Officer | Oct 16 '25 | Sell | $6.35 | 12,169 | $77,273.15 | 197,287 | |
| Elazzouzi Amy | AURA | Senior Vice President, Finance | Aug 18 '25 | Sell | $6.70 | 7,722 | $51,737.40 | 85,662 |
Latest Aura Biosciences Inc. News
AURA Breaking Stock News: Dive into AURA Ticker-Specific Updates for Smart Investing
MT Newswires
6 months ago
Aura Biosciences Prices $75 Million Offering of Shares, Warrants
GlobeNewswire
6 months ago
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
MT Newswires
6 months ago
Aura Biosciences Launches Proposed Public Offering of Shares, Warrants
GlobeNewswire
6 months ago
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire
6 months ago
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
6 months ago
Aura Biosciences to Participate in Upcoming Investor Conferences
Insider Monkey
7 months ago
Is Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential?
GlobeNewswire
7 months ago
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Compare AURA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AURA Aura Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.